Get the latest news, insights, and market updates on DYN (Dyne Therapeutics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best upside stocks to buy now. On November 25, Bernstein raised the firm’s price target on Dyne Therapeutics to $21 from $12 with a Market Perform rating on the shares. Bernstein believes that Dyne Therapeutics has a favorable risk-reward profile. The next major catalyst expected for the […] Nov 30, 2025 - $DYN
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. Accelerated Approval in Q2 2026 - - FDA recently granted Breakthrough Therapy Designation to z-rostudirsen for the treatment of patients with DMD amenable to exon 51 skipping - - U.S. sites activated in ACHIEVE trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in DM1; c Nov 5, 2025 - $DYN
Assessing Dyne Therapeutics (DYN) Valuation Following Recent Share Price Rally
Dyne Therapeutics (DYN) shares have seen substantial movement in recent weeks, gaining more than 70% over the past month. This comes after a period of relative underperformance earlier in the year. See our latest analysis for Dyne Therapeutics. After languishing for much of the year, Dyne Therapeutics’ sharp rally has put it back in the spotlight. Although the 1-year total shareholder return is still down 21.5%, the recent 30-day share price return of 72.9% suggests momentum has shifted... Nov 3, 2025 - $DYN
Dyne Therapeutics to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Monday, November 10, 2025 at 10:00 a.m. ET in Boston, MAStifel 2025 Healthcare Conference, firesid Nov 3, 2025 - $DYN
Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger
We recently published 10 Big Names Crushing Wall Street. Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the top-performing stocks on Monday. Dyne Therapeutics soared by 41.18 percent on Monday to close at $24.17 apiece following a comment from investment firm Jefferies that it would likewise benefit from Novartis’ $12 billion planned acquisition of its peer, […] Oct 28, 2025 - $DYN
Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal
Investing.com -- Shares of Avidity Biosciences (NASDAQ:RNA) jumped more than 42% in premarket trading on Monday, while Dyne Therapeutics (NASDAQ:DYN) climbed over 20%, after Novartis announced an agreement to buy Avidity for about $12 billion in cash. Oct 27, 2025 - $DYN
Jefferies sees Dyne as key beneficiary of Novartis’ Avidity buyout
Investing.com -- Dyne Therapeutics is positioned as a major beneficiary of Novartis’ $12 billion acquisition of Avidity Biosciences, Jefferies analysts said, calling the deal a strong validation of RNA-based therapies for rare muscle diseases. Oct 27, 2025 - $DYN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple